An observational study in Maternal Depression, Maternal Anxiety and Preterm Birth Infants, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Recruiting at 1 site in Italy. Open to participants aged 24 Weeks to 30 Weeks. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Depression with a site in Italy — 32 open to participants now, 33 under way, 2 of them phase 3. Depression · Italy.
Among the 102 studies in Depression with a site in Italy, this one is the 21st largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2026, is one of 28 observational ones, reaches primary completion later than 22 of the 32 other live ones, and was the 102nd registered.
8,601 studies on the registry are indexed under Depression; 1,735 are open to participants now.
Browse Depression studies →32 of the 102 studies in Depression with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 65–85
IRCCS Centro Neurolesi Bonino Pulejo · Sites in Italy
Ages 18–60
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 50–80
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 1,097 Depression studies recruiting now, 473 (43%) set no upper age limit and 523 (48%) stop at 75 or younger; 206 take children under 18; 314 take healthy volunteers.
This study: 24 Weeks to 30 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is below the median of 175 across 1,261 observational studies indexed under Depression.
Median enrollment 102 across the 74 interventional studies, 200 across the 28 observational. Of the 50 that completed or were terminated, 10 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 102 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is the lead sponsor of 235 studies on the registry; 79 are open to participants now.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico has 3 studies filed under Depression — fewer than ten, so there is no comparison to draw.
4 of the studies in Depression with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589544University Hospital of FerraraNon-pharmacological Care for Depression in Cancer Patients Using VR and TMS | 2026-12-31 |
| NCT06724029Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNeurosurgical Outcome Network | 2027-06 |
| NCT07943130Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoExploring the Interplay Between Maternal Stress, Human Milk, and Epigenetic Changes in Preterm Infant's Neurodevelopment | 2027-06-01 |
| NCT06395558Azienda Usl di BolognaintErnet-based iNterventions FOR Cardiac arrEst suRvivors | 2027-08-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 102 studies in Depression with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preterm birth represents a major challenge in pediatric healthcare, as preterm infants are at increased risk of neonatal complications and long-term neurodevelopmental impairments. Several factors may contribute to these outcomes, including gestational age at birth, postnatal comorbidities, and the neonatal intensive care unit (NICU) environment. Furthermore, preterm birth and prolonged hospitalization may negatively affect maternal psychological well-being, increasing the risk of stress, anxiety, and depression. These conditions may influence maternal sensitivity and responsiveness, mother-infant interactions, and infant neurodevelopment.
Emerging evidence suggests that maternal mental health may affect infant neurodevelopment through both direct biological mechanisms, such as epigenetic regulation, and indirect pathways, including changes in breast milk composition. Cortisol, a stress-related hormone present in breast milk and saliva, may play a role in stress regulation and neurobehavioral development. In particular, the methylation of Long Interspersed Nuclear Element-1 (LINE-1 or L1), a mobile genetic element involved in genomic regulation, may be influenced by environmental factors and early maternal care. Preliminary findings indicate that preterm infants exhibit lower L1 promoter methylation levels at birth than term infants, while early maternal care may modulate these levels and support neurobehavioral development.
The EMBRACE study aims primarily to investigate the relationship between biological maternal stress, measured through salivary cortisol levels, and L1 promoter methylation in blood samples collected from preterm infants from birth to 12 months of corrected age. Secondary objectives include examining this relationship in buccal swab samples, assessing associations between maternal perceived stress, anxiety, and depression and infant L1 methylation, and investigating the relationship between maternal psychological and biological stress indicators and infant neurodevelopmental outcomes. The study will also explore associations between perceived maternal stress and cortisol concentrations in breast milk and saliva, as well as longitudinal changes in L1 methylation.
This is a non-pharmacological, observational cohort study conducted at the Neonatology and Neonatal Intensive Care Unit of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy. Participants will include preterm infants born between 24+0 and 30+6 weeks of gestational age and their mothers. Assessments will be conducted at five time points: birth, transition to intermediate care or 34 weeks of postmenstrual age, hospital discharge, 6 months, and 12 months of corrected age. Maternal assessments will include standardized questionnaires evaluating stress, anxiety, and depression, as well as cortisol measurements in saliva and breast milk. Infant assessments will include L1 methylation analyses in blood and buccal samples and standardized neurodevelopmental evaluations as part of routine clinical follow-up. No additional invasive procedures will be performed, as blood samples will be collected during routine clinical care.
The study is expected to improve understanding of the relationships between maternal stress, anxiety, depression, epigenetic regulation, and neurodevelopment in preterm infants. It will also investigate the potential role of breast milk cortisol in these associations. Ultimately, the findings may contribute to the development of early interventions aimed at improving neurodevelopmental outcomes in preterm infants and supporting maternal psychological well-being.
All preterm infants born at the SC Neonatologia e Terapia Intensiva Neonatale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano and their mothers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epigenetic changes on LINE1 (blood samples)
epigenetic analysis is performed on cord blood samples collected at birth, at transition to intermediate care and at hospital discharge on peripheral blood samples
Time frame: up to 48 weeks post menstrual age
Maternal salivary cortisol
Collected at birth, transition to intermediate care, discharge
Time frame: up to 12 months corrected age of the infant
Human milk cortisol concentrations
Collected at birth, transition to intermediate care, discharge
Time frame: up to 6 months corrected age of the infant
Buccal swab
Collected at birth, 34 weeks GA, discharge, 6 and 12 months corrected age
Time frame: up to 12 months corrected age
Neurological outcome
Hammersmith neonatal neurological examination performed at NICU discharge
Time frame: up to 44 weeks post menstrual age
Neonatal Visual Assessment
Neonatal visual function in assessed at discharge using the Visual Assessment battery developed by Ricci et al. The assessment has 9 items and each one is scored as normal or abnormal according to the description given by the authors.
Time frame: up to 44 weeks post menstrual age
Neonatal behavior
Neonatal behavior is assessed using the Neonatal Behavior Assessment Scale, and in particular the areas of state organization, state regulation, and the autonomic system. Each item will be scored according to the description given by the author of the assessment
Time frame: up to 44 weeks post menstrual age
Neurodevelopmental outcome
Bayley scales to assess neurodevelopment at 6 and 12 months corrected age. The normal range for the composite score is 100 +/- 15 points. Higher scores mean better outcomes.
Time frame: from 6 to 12 months corrected age
Maternal depression
Assessed with the Edinburgh Postnatal depression scale. Responses are scored 0 to 3. A score above 8 is considered pathological in the post partum period. It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age.
Time frame: up to 12 months corrected age of the infant
Maternal stress in the NICU
Assessed with the Parental Stressor Scale: Neonatal Intensive Care Unit (PSS:NICU). It is composed of 35 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressfull). It will be administered at birth, at transition to intermediate care and at NICu discharge.
Time frame: up to 12 months corrected age of the infant
Maternal bonding
Assessed with the Postpartum Bonding Questionnaire (PBQ) administered at NICU discharge, 6 and 12 months corrected age. A score above 26 is considered pathological.
Time frame: up to 12 months corrected age of the infant
Maternal anxiety and depression
Assessed with the hospital anxiety and depression scale (HAD-S). It will be administered at birth, at transition to intermediate care, at NICu discharge at 6 and 12 months corrected age. A score from 0 to 7 is normal, 8-10 borderline and 11-21 score in the clinical range.
Time frame: up to 12 months corrected age of the infant
Parenting stress
Assessed with the Parenting Stress Index Scale. Administered at 6 and 12 months corrected age. It is composed of 36 items that are scored on a 5-point Likert scale ranging from 1 (not stressful at all) to 5 (extremely stressful)
Time frame: up to 12 months corrected age of the infant
Plan to share: Undecided
Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
Of 462 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 9 months is below that.
Counting every sponsor, half of 495 studies reached it within 32 months; a quarter within 13 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico →